Avandia - Newsfeeds
- Bloomberg - Europe's biggest drugmaker posted a 10 percent drop in fourth-quarter net income as sales of the Avandia diabetes pill decreased by more than half. The company also said earnings will decline this year. Renault plunged 12 percent. Merrill ...
- Baltimore Sun - Researchers said they don't know what caused the spike in deaths but said it can't be blamed on Avandia - a diabetes medication linked last year to an increased risk of heart attacks - even though some volunteers were taking the drug. "Clearly we did ...
- Guardian Unlimited - Glaxo, which has blamed safety concerns over its Avandia diabetes pill and increased competition from generic drugs, lost another 8p to £10.70, following Thursday's 89p fall. Selling spilled over into the rest of the sector and AstraZeneca was down ...
- BusinessWeek - A shock profit warning from GlaxoSmithKline sent its shares plummeting yesterday after the drug giant said "the shadow of Avandia would continue to make life difficult" in 2008. Sales of the blockbuster diabetes drug Avandia fell by almost a third in ...
- WebWire - The study is continuing, and patients will continue to receive Avandia (rosiglitazone maleate) and all other diabetes medicines; however, the goal for glucose control will be adjusted. Patients will be moved from intensive management to standard ...
- MSN MoneyCentral - The stock fell Thursday after Glaxo said its fourth-quarter profit fell 10 percent, and forecast additional declines in 2008 due to softer sales of its diabetes drug Avandia. French biotechnology company Flamel Technologies SA gave up 10 cents to $8.91
- Globe and Mail - Recent high-profile examples of drugs - such as Vioxx and Avandia - that had to be pulled from the market even after going through rigorous premarket tests, highlight the need for thorough trials both before and after drugs are available to the ...
- International Herald Tribune - GlaxoSmithKline (GSK) took a beating on Thursday after the drugmaker warned 2008 earnings would fall due to sliding sales of diabetes drug Avandia and more generic competition. WestLB, Citigroup and Goldman all cut their price targets on GSK, which ...
- Bloomberg - The company blamed the forecast on lower sales of the diabetes pill Avandia and generic competition to other top products facing patent expirations this year. Societe Generale dropped 4.2 percent to 77.17 euros. French police widened ...
- Bloomberg - Glaxo blamed the forecast on lower sales of the diabetes pill Avandia and generic competition to other top products facing patent expirations this year. BP, Europe's second-largest oil company, climbed 0.8 percent to 540.5 pence. Technip ...
- Bloomberg - Glaxo blamed the forecast on lower sales of the diabetes pill Avandia and generic competition to other top products facing patent expirations this year. TeliaSonera fell 9.7 percent to 51 kronor after Sweden's largest telephone company ...
- CNBC - The group said yesterday that it expects the impact of lower Avandia sales together with increased generic competition to lead to a mid-single digit percentage decline in business performance EPS, at constant exchange rates, in 2008. Fitch said the ...
- Times Online - Nearly £5billion was wiped from the value of GlaxoSmithKline after Europe's biggest drugmaker said that its 2008 earnings would fall because of tougher generic competition and sliding sales of Avandia, its diabetes drug. BT closed down 10 per cent ...
- Times Online - GlaxoSmithKline reported sliding 2007 profits and gave warning yesterday that earnings this year were under pressure from collapsing sales of Avandia, its diabetes drug, and intense competition from manufacturers of generic treatments. JP Garnier ...
- Daily Telegraph - A near halving of revenue from its second best-selling drug, the diabetes blockbuster Avandia, and increased competition from generics resulted in a 10pc fall in profits before tax to £1.5bn for the fourth quarter. Although chief executive Jean ...
- Fort Wayne Journal Gazette - Researchers found no link to the diabetes drug rosiglitazone, trade-named Avandia, which previously has been linked to deaths from heart disease. Mastbaum and other doctors emphasized that the benefits of lowering blood sugar to currently recommended ...
- Guardian Unlimited - In one of his last presentations before retirement in May, Garnier criticised the reporting of scientific developments and appeared to partly blame journalists for the furore surrounding GSK's diabetes drug Avandia, sales of which plunged when a ...
- Reuters UK - ... have grown impatient with the underperformance of the company's shares. The shares fell around 8 percent on Thursday to the lowest level in more than three years, as the forecast 2008 earnings slowdown -- due to slowing sales of diabetes drug Avandia ...
- Philadelphia Inquirer - Avandia. Sales of the diabetes drug, the company's second-biggest seller, slid 55 percent in the fourth quarter. The decline sliced $1 billion from sales, capping a swoon that began with a May 2007 analysis in the New England Journal of Medicine ...
- BusinessWeek - A shock profit warning from GlaxoSmithKline sent its shares plummeting yesterday after the drug giant said "the shadow of Avandia would continue to make life difficult" in 2008. Sales of the blockbuster diabetes drug Avandia fell by almost a third in ...
Want to contact an Avandia lawyer in District of Columbia? ...Get a free case evaluation from one of our Avandia lawyers in District of Columbia now.
Pages: Previous 1 2 3 4 5 6 7 8 ... Next
